Amicus Therapeutics, Inc.
http://www.amicusrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amicus Therapeutics, Inc.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
US FDA’s Missed User Fee Goals Spiked In 2023 – And Not Just Because Of COVID-19
CDER missed six goal dates among its 2023 novel approvals, reflecting safety concerns as well as pandemic-related inspection delays; Duchenne muscular dystrophy accelerated approval disagreements caused the biologics center’s lone missed goal.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Callidus Biopharma
- Celenex
- MiaMed, Inc.
- Scioderm, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice